Abstract. Retinoids have been used as potential chemotherapeutic or chemopreventive agents because of their differentiative, anti-proliferative, pro-apoptotic and antioxidant properties. We investigated the effect of all trans-retinoic acid (ATRA) at different stages of the neoplastic transformation using an in vitro model of breast cancer progression. This model was previously developed by treating the MCF-10F human normal breast epithelial cells with high dose of estradiol and consists of four cell lines which show a progressive neoplastic transformation: MCF-10F, normal stage; trMCF, transformed MCF-10F; bsMCF, invasive stage; and caMCF, tumorigenic stage. In 3D cultures, MCF-10F cells form tubules resembling the structures in the normal mammary gland. After treatment with estradiol, these cells formed tubules and spherical masses which are indicative of transformation. Cells that only formed spherical masses in collagen were isolated (trMCF clone 11) and treated with ATRA. After treatment with 10 or 1 µM ATRA, the trMCF clone 11 cells showed tubules in collagen; 10 and 43% of the structures were tubules in cells treated with 10 and 1 µM ATRA, respectively. Gene expression studies showed that 207 genes upregulated in transformed trMCF clone 11 cells were downregulated after 1 µM ATRA treatment to levels comparable to those found in the normal breast epithelial cells MCF-10F. Furthermore, 236 genes that were downregulated in trMCF clone 11 were upregulated after 1 µM ATRA treatment to similar levels shown in normal epithelial cells. These 443 genes defined a signature of the ATRA re-programming effect. Our results showed that 1 µM ATRA was able to re-differentiate transformed cells at early stages of the neoplastic process and antagonistically regulate breast cancer associated genes. The invasive and tumorigenic cells did not show any changes in morphology after ATRA treatment. These results suggest that ATRA could be used as a chemopreventive agent to inhibit the progression of premalignant lesions of the breast.
Introduction
Vitamin A is obtained through the diet in the form of retinol, retinyl ester or β-carotene (1) . Retinoic acid (RA) is one of the principal active metabolites of vitamin A which plays a critical role in cell proliferation, differentiation and apoptosis in normal tissues during embryonic development (2) . RA induces differentiation in many cell types and is the most widely used differentiating therapeutic agent (3, 4) . Retinol has 6 biologically active isoforms that among others includes all-trans (ATRA, tretinoin) and 9-cis RA (alitretinoin); ATRA is the predominant physiological form (5) . RA mediates the transcriptional regulation of several genes by binding to the nuclear retinoic acid receptors (RARs), namely RARα, RARβ and RARγ (6, 7) . Like other nuclear receptors, RARs contain a domain that mediates interaction with ATRA, a zinc finger-containing DNA binding domain that binds to RA response elements (RAREs) in target genes, and a dimerization domain that engages members of the retinoid X receptor (RXR) subfamily in RXR/RAR heterodimers (8) . Different isomers activate different receptors and thus lead to different biological effects. RARs can be activated by both all-trans (ATRA) and 9-cis-RA, while RXR are exclusively activated by 9-cis RA; however, due to the conversion of ATRA to 9-cis RA, high concentrations (10 -5 M) of ATRA can also activate gene transcription in cells transfected with RXRs (9) . It has also been shown that retinoids exert their effects via the nuclear receptor independent pathway (5) .
RA and its derivatives are promising anti-neoplastic agents endowed with both therapeutic and chemo-preventive potential because they are able to regulate cell growth, differentiation and apoptosis (10, 11) . It is believed that the anti-neoplastic pathways induced by RA are regulated predominantly by RAR-β, which is known to induce apoptosis; thus it has been suggested that RAR-β plays a critical role in mediating the growth arrest and differentiation in several breast cancer cell types (12) (13) (14) .
We have developed an in vitro-in vivo model of breast cancer progression by treating the human normal-like breast (15, 16) . This model consists of four cell lines: i) the spontaneously immortalized cell line MCF-10F, which is considered to be a normal-like breast epithelial cell line; ii) the transformed trMCF cells; iii) the invasive bsMCF cells; and iv) cells isolated from xenografts, caMCFs, which show all characteristics of fully malignant breast cancer cells (Fig. 1) . Gene expression studies showed the highest number of deregulated genes in caMCF, being slightly lower in bsMCF, and lowest in trMCF and, this order was consistent with the extent of chromosome aberrations (caMCF>bsMCF>>trMCF) (16) . This model of breast cancer progression resembles the different steps of neoplastic transformation of the mammary gland; it is widely held that breast cancer initiates as the premalignant stage of atypical ductal hyperplasia (ADH), progresses into the pre-invasive stage of ductal carcinoma in situ (DCIS), and culminates in the potentially lethal stage of invasive ductal carcinoma (IDC) (17) . In collagen, the normal-like MCF-10F cells form tubules resembling the structures observed in the normal mammary gland although after treatment with estradiol, the transformed trMCF cells form tubules and spherical masses, which are indicative of cell transformation (8, 19) . The spherical masses showed a partial filling of the lumen that would result from decreased central apoptosis, enhanced cellular proliferation or both (18) . The filling of the lumen of the tubular structures of the breast is the earliest morphologic alteration and is common in atypical ductal hyperplasia and ductal carcinoma in situ (DCIS) (18) . In the presented study, we studied the effect of all trans-RA (ATRA) using this model of breast cancer progression. Our results showed that ATRA was able to re-program early transformed cells to a normal stage. Vibrio cholerae toxin, 10 mg/l insulin, 0.5 mg/l hydrocortisone, 1.05 mM calcium, antibiotics and antimicotic (100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin). A 10-mM solution of all trans-retinoic acid (ATRA, Cat# R2625, Sigma, St. Louis, MO) was prepared as a stock solution by dissolving ATRA in dimethylsulphoxide (DMSO). The trMCF clone 11 was isolated by seeding 100-1,000 trMCF cells in a 100-mm cell culture plate and after 1 day in culture, several colonies were isolated by ring cloning. The trMCF clone 11 cells were generated by expanding the cells from one of these colonies; trMCF clone 11 cells only formed spherical masses on collagen. To study the effect of ATRA, trMCF clone 11 cells were treated continuously for 26 days with 10 -5 M (10 µM) to 10 -8 M (0.01 µM) ATRA (media was replaced daily). As control, the cells were treated with 0.1% DMSO (vehicle). The bsMCF and caMCF cells were treated with 10 -5 to 10 -8 M ATRA alone or in combination with 2.5 µM 5-aza-dC.
Materials and methods

Cells and media.
Collagen assays. The cells were resuspended at a final density of 1.5x10 4 cells/ml in collagen matrix consisting of 2.68 mg/ml (89.3%) type I collagen (PureCol, Inamed Biomaterials Co., Fremont, CA), 8% 12.5X DMEM-F12 with antibiotics, 0.1 mg/ml insulin, 14 mM NaHCO 3 and 0.01 N NaOH. A total of 400 µl (3,000 cells) were plated on the top four 24-well chambers pre-coated with 400 µl of 89.3% collagen mix. Per each treatment, cells were plated in 4 wells and fed daily with the medium described before. The structures in collagen matrix were observed daily under an inverted microscope and at the end of the observation period (8 days), the structures (spherical masses, tubules and intermediate structures) were counted, photographed and fixed in 10% neutral buffered formalin and processed for histological examination. Results were expressed as the total number of structures per well (spherical masses, tubules and intermediate structures) and percentage of the different structures per treatment. The t-test was used to determine if the differences were significant. Invasion assays. Cell invasion in real-time were performed using xCELLigence RTCA DP device from Roche Diagnostics (Mannheim, Germany). For this purpose, each well of the upper chamber of the CIM-Plate 16 was covered with Matrigel (BD Biosciences, Franklin Lakes, NJ) basement membrane matrix (1:20 in cell culture media) and 10% fetal bovine serum (chemo-attractant) was added in the lower chamber. A total of 40,000 cells suspended in 100 µl serum free media were seeded per well in CIM-Plates 16 (Roche Diagnostics). Data acquisition and analysis was performed with the RTCA software (version 1.2, Roche Diagnostics). Changes in impedance from cells that invade and migrate to the underside of wells were recorded and monitored for a total of 24 h.
Gene expression profiling. RNA was isolated from the cells using RiboPure™ kit (Life Technologies, Frederick, MD) and RNA quality was controlled using the Agilent 2100
Bioanalyzer. Gene expression studies were performed using Affymetrix U133 Plus 2.0 (Affymetrix, Santa Clara, CA) human oligonucleotide microarrays containing over 47,000 transcripts and variants, including 38,500 well characterized human genes. After hybridization, the chips were scanned using GeneChip Scanner 3000. The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100. Background correction and normalization was done using Iterative Plier 16 with GeneSpring V11.5 software (Agilent, Palo Alto, CA). The criteria for differentially expressed genes was set at ≥2-fold changes (p-value <0.05). The differentially expressed gene list was loaded into Ingenuity Pathway Analysis (IPA) 8.0 software (Ingenuity Systems, Redwood City, CA) to perform biological network and functional analyses. 
Results
Treatment with ATRA induced branching morphogenesis in early transformed breast epithelial cells. MCF-10F cells
are normal-like breast epithelial cells that form tubules in collagen matrix (3D culture); when these cells were treated with high dose of estradiol (70 nM), the cells (trMCF) formed tubules and spherical masses. To isolate transformed cells that only form spherical masses, trMCF cells were seeded at low density in cell culture dishes and several clones were isolated by ring cloning. One of these clones, trMCF clone 11, did not form tubules in collagen; instead these cells formed spherical masses and intermediate structures ( Fig. 2A and B) . The trMCF clone 11 cells were treated continuously for 26 days with 10 -5 to 10 -8 M all trans-retinoic acid (ATRA) and, we found that cells treated with 10 -5 and 10 -6 M ATRA were able to form tubules in collagen ( Fig. 2C  and D) . Furthermore, the spherical masses formed by trMCF clone 11 treated with 10 -5 and 10 -6 M ATRA ( Fig. 2C and D) were smaller compared to the ones formed by the controls ( Fig. 2A and B Fig. 2A and B) . The number of spherical masses, intermediate structures and tubules for trMCF clone 11 cells treated with different concentrations of ATRA was counted (Fig. 3) . The total number of structures in collagen was significantly lower in cells treated with ATRA compared with the controls suggesting that ATRA treatment decrease the proliferation rate of the cells (p<0.01) (Fig. 3A) . The control trMCF clone 11 showed spherical masses and intermediate structures but no tubules in collagen while cells treated with 10 -6 and 10 -5 M ATRA formed tubules and less spherical masses (Fig. 3A) . The cells treated with 10 -5 or 10 -6 M ATRA formed significantly less spherical masses than the cells treated with 10 -7 or 10 -8 M ATRA (p<0.01) (Fig. 3A) . A total of 43% of the structures were tubules in the wells containing cells treated with 10 -6 M ATRA and 10% tubules in wells with 10 -5 M ATRA-treated cells (Fig. 3B ). The invasion capacity of trMCF clone 11 was studied before and after ATRA treatment but, no differences were observed (Fig. 4) . The bsMCF and caMCF cells did not show any changes in their morphology or invasion capacity after treatment with ATRA alone or in combination with the demethylating agent 5-aza-cytidine (data not shown).
Treatment with ATRA re-programmed gene expression of early transformed cells. As trMCF clone 11 cells that only formed spherical masses on collagen were able to form tubules after treatment with 10 -5 or 10 -6 M ATRA, gene expression studies were performed on these cells. The microarray data have been deposited into the NCBI gene expression omnibus (GEO) datasets (GSE51549). The unsupervised sample classification by PCoA (principle coordinate analysis) revealed that trMCF clone 11 cells treated with 10 -5 or 10 -6 M ATRA demonstrated a major difference with trMCF clone 11 cells, and a minor difference with MCF-10F; also sample differences between 10 -5 M ATRA and 10 -6 M ATRA were weak (Fig. 5) . Although, trMCF clone 11 cells treated with 10 -5 M ATRA and 10 -6 M ATRA showed minor differences at the expression level, we considered trMCF clone 11 treated with 10 -6 M ATRA for the expression analysis since the number of tubules in collagen matrix was higher for this concentration (43% tubules with 10 -6 M ATRA vs. 10% tubules with 10 -5 M ATRA). For gene expression studies, three experimental groups were compared using empirical Bayesian-moderated t-test implemented in R package 'limma': the normal breast epithelial cells MCF-10F, the cells transformed by treatment with estradiol trMCF clone 11 (that only formed spherical masses on collagen) and the trMCF clone 11 after treatment with 10 -6 M ATRA. We generated three gene lists at criteria of fold change ≥2 and p≤0.05: gene list-1 (trMCF clone11 vs. MCF-10F) with 1,409 probes (613 probes upregulated; 796 probes downregulated), gene list-2 (ATRA trMCF clone 11 vs. trMCF clone 11) with 1,859 probe sets (1,053 probes upregulated; 806 probes downregulated) and gene list-3 (ATRA trMCF clone 11 vs. MCF-10F) with 870 probe sets (308 probes upregulated; 562 probes downregulated) (Fig. 6 ). Most importantly, 207 genes (271 probes) upregulated in the transformed trMCF clone 11 (compared to the normal MCF-10F) were downregulated after treatment with 10 -6 M ATRA ( Fig. 6 and Table IA ) and 236 genes (316 probes) that were downregulated in trMCF clone 11 (compared to MCF-10F) were upregulated by 10 -6 M ATRA treatment ( Fig. 6 and Table IB ). These 443 genes defined a gene signature programming the reverse-transformation effect by ATRA (Table I ). The relatively smaller number of significant probe sets in gene list-3 compared with other gene lists (Fig. 6 ) further supported the findings that ATRA-treatment reprograms the gene expression status of trMCF clone 11 cells to MCF-10F.
Ingenuity pathway analysis (IPA) revealed 4 canonical pathways significantly dysregulated in the transformed cells trMCF clone 11: aryl hydrocarbon receptor signaling, retinoic acid activation, xenobiotic metabolism signaling and molecular mechanism of cancer (Table II) . Several genes of these pathways that were up-or downregulated in trMCF clone 11 show similar levels of expression to MCF-10F after trMCF clone 11 was treated with 10 -6 M ATRA (Table II and Fig. 7) . Genes from the aryl hydrocarbon receptor signaling ALDH1A3, CCND1, TGFBR2, TGM2 and TFDP1 were downregulated in the transformed cells trMCF clone 11 when compared to their expression in the normal breast epithelial cells MCF-10F and, the expression of these genes was upregulated after these cells were treated with 10 -6 M ATRA reaching similar levels to the expression in MCF-10F (Table II and Fig. 7) . One of the functions that show enrichment of dysregulated genes in the transformed trMCF clone 11 cells is cell morphology and the expression of most of these genes reached similar levels to MCF-10F after trMCF cells were treated with 10 -6 M ATRA. The expression of some genes related to cell morphology such as PLD1, CD44, STX6, STMN3, ATF2, ETS2, NEK2, HAS3, MGP, GNA13 were upregulated in the transformed trMCF clone 11 and their expression reached normal levels after 10 -6 M ATRA treatment (Fig. 7) ; other genes related to ALDH3A2  DSC3  KLHDC8B  PLAG1  TMEM167B  ALDOC  DUSP5P  LCA5  PLD1  TMEM27  ALPK1  EFHC1  LOC100288092  PLD6  TMEM40  ANKRD37  EFNB3  LOC100289187  PLK1S1  TMEM59  AQPEP  EPB41L4B  LOC100505894  POFUT2  TNFRSF25  ARG2  ERCC1   a   LOC100506057/STK32C  POLR1D  TNFSF11  ARHGAP19  ETS2   a   LOC100507303  PPIL6  TNKS  ARHGEF10  FABP6  LOC100507547  PPOX  TP63  ATF2  FAM117A  LOC100507644  PPP1R13L  TPD52L1   a   ATG14  FAM168A  LOC439938  PPP1R3C  TPRG1  ATP2C2  FAM46C  LOC642587  PRKAB2  TRAF3IP2  ATP5C1  FAT2  LOX  PRMT2  TRAPPC6A  BCAS4  FBXO2  LRIG1  PROCR  TSC22D3  BFSP1  FEM1B  LYST  PTEN  TTBK2  BLNK  FLCN  MAP2K5  PTEN/PTENP1  TTC39B  BTBD3  FLJ37644  MAPT  PTPN14  TXNIP  C11orf80  FLJ45244  MGEA5  RAB11FIP4  UFM1  C16orf46  FNBP1L  MGP   a   RAB38  UGT1A1/1A4/1A6/1A8/1A9/1A10  C17orf39  FNTA  MLF1  RAB40C  USP3  C17orf48  FNTB  MRAP2  RAB4A  USP32  C1orf133  FSIP1  MXD1  RAB7L1  VPS8  C1orf161  FXYD2  MYLIP  RASSF6  WAC  C20orf111  GBAS  N4BP2L1  RMND1  WDR59  C21orf7  GGNBP2  NDE1  RNF169  WDR91  C5orf41  GGTA1  NDUFB4  SCARA3  WWOX   a   C7orf68  GIT2  NEK2  SCRG1  YOD1  C9orf9  GJA3  NEURL1B  SEMA6A  ZBTB34  CCDC28A  GKAP1  NFKBIL1  SFT2D1  ZFAND5  CD44   a   GNA13  NGLY1  SHOX2  ZNF836  CELSR2  GNAI1  NMNAT3  SLC25A37  ZNRF1  CLCA2  GOSR2  NPL  SLC2A12  CMBL  GPM6A  OGFRL1  SLC2A9  COBL  GPNMB  PALMD  SLC5A3  CRIP2  H19  PDCD4   a   SOCS3  CSNK2A2  HAS3  PDCD5  SORL1  CYP1B1  HBP1  PDE7A  SPATA17  CYP39A1  HERPUD1  PDZD2  STAU2  DBP  HMGCL  PER1  STMN3  DCD  IFNAR1  PER3  STX6  DDAH2  IRF6  PHF21A  SUSD4  DDC   a   IRX2  PHLDB3  TESK2  DDIT3  KCMF1  PHTF2  THBS2  DHX40  KDM5B  PIK3CD  THSD1///THSD1P1 Genes upregulated in trMCF clone 11 that were downregulated after 10 -6 M ATRA-treatment to similar levels found in MCF-10F are indicated. a Genes with binding sites for RARα or RARβ described by Hua et al (29) . ABHD13  COX7B  HIATL1  OSTM1  SLC43A3  TSPAN2  ACP2  CRELD2  HIGD1A  P2RY2  SMPDL3A  UBE2N   a   ADAM12  CST6   a   HOXA11  PAPPA  SNRNP25  UBE2Q1  ALDH1A3  CSTF2  HPGD  PARVA  SNX19  UBP1  ANO1  CYB561D2  HS3ST1  PCSK5  SOAT1  UNK  AOX1  DCBLD2  HS6ST2  PDE12  SPAG1  VARS2  APOL6  DHRS9  IFI44  PHACTR3  SPATA13  VGLL3  ARGLU1  DHX9  IFIT3  PHLDA1  SRPX2  VSIG10  ARHGAP26  DNAJA1  IFIT5  PHLDA2  SRSF10  ZADH2  ARHGAP42  DOLK  IFNAR1  PITPNC1  SRSF2IP  ZBED4  ARHGDIB  DPH3  KHNYN  PKIB  SSPN  ZDHHC2  ARIH2  EFCAB2  KLHL18  PLCXD2  STK39  ZMPSTE24  ASPHD2  EFNB2  KLHL23  PLGLA/PLGLB1/PLGLB2  STS  ZNF252  ATP6V0A2  EHD4  KRT80  PNO1  STYK1  ZNF271  B3GALNT1  EIF2AK1  LOC100131993  PNPLA3  SUPT7L  ZNF326  BRI3BP  EIF5B  LOC100505759  PODXL  SUSD5  ZNF35  BTG1  ELOVL6  LOC100507192  POLR3K  SYNCRIP  C12orf26  ENC1   a   LOC283278  PPP2R1B  SYNJ2BP  C12orf5  ENY2  LOC728903  PRPS1  SYTL2  C1GALT1C1  ERLIN2  MACC1  PRR15  SYTL5  C1orf116  EXOG  MARCKS  PSCA  TBC1D30  C1orf135  FADS1   a   MAT2A  PSME3  TFDP1  C1orf212  FAIM  MCFD2  PTGR1  TFRC  C1orf226  FAM118B  MEIS3P1  PTP4A2  TGFB2  C6orf223  FAM119A  MFAP3L  PTPRB  TGFBR2   a   CALM1   a   FAM83A  MFI2  PTPRJ  TGM2  CCDC68  FBXW2  MFSD1  RABIF  THSD4  CCDC88A  FDX1  MICALL1  RBM25  TIMM23  CCND1   a   FN1   a   MMACHC  RBM45  TIMM8A  CDA  FNIP2  MRPL35  RGS17  TIMM8B  CDC42EP2  FRMD3  MST1R  RHOBTB1  TLCD1  CDH2  FUCA1  MTERFD3  RHOF  TLR3  CEP78  FXN  MYEOV  RPL27A  TLR4  CFH/CFHR1  FZD8  MYO5C  RPS6KA2  TMC5  CFI  GALNT7  NAA40  S1PR3  TMEM133  CHAC2  GATAD2A  NAV3  SAMHD1  TMEM177  CHML  GBP1  NECAP1  SCEL  TMEM9B  CHRNA5  GDA  NIPAL1  SGK223  TP53I3  CLDN23  GGCX  NMI  SH3TC2  TPCN2  CMAH  GPATCH2  NRP2  SLC16A5  TRAK2  CNPY2  GPX8  NSD1  SLC1A1  TRIM45  COL4A3  GXYLT1  OLAH  SLC35B4  TRIOBP  COL4A4  HAS2  OR7E14P  SLC35C1  TRNT1  COX7A1  HERC6  OR7E47P  SLC37A1  TSPAN12 Genes downregulated in trMCF clone 11 that were upregulated after 10 -6 M ATRA-treatment to similar levels found in the normal breast epithelial cells MCF-10F.
a Genes with binding sites for RARα or RARβ described by Hua et al (29) .
cell morphology such as PHLDA1, GBP1, HS6ST2 and TLR3 were downregulated in trMCF clone 11 and their expressions increased after 10 -6 M ATRA treatment reaching similar levels to those found in the normal MCF-10F breast epithelial cells (Fig. 7) . Also, the expression of several genes that encode enzymes involved in chromatin modifications such as MGEA5, ATF-2, KDM5B, PRMT2 (PRM2), PHF21A and NSD1, were dysregulated in trMCF clone 11, reaching normal levels after 10 -6 M ATRA treatment (Fig. 7) .
Discussion
In this study we showed that all trans-retinoic acid (ATRA) induced branching of early transformed human breast epithelial cells. The transformed trMCF clone 11 cells form spherical masses in collagen (3D culture) and treatment with 10 -6 M ATRA produced a significant decrease in spherical masses and an increased number of tubules. Cells at an advanced stage of transformation (bsMCF and caMCF) did not show any change in morphology after being treated with ATRA. Our previous results showed that RARβ (retinoic acid receptor β) was unmethylated in MCF-10F and trMCF cells and became hypermethylated at the invasive (bsMCF) and tumorigenic (caMCF) stages (19) ; although bsMCF and caMCF were treated with 5-aza-dC to reactivate the expression of RARβ in combination with ATRA, no changes in the phenotype of these cells in collagen were observed. Our results indicate that ATRA is able to re-differentiate early transformed cells to a normal stage but, not tumor cells at later stages of the neoplastic process. We previously showed that bsMCF and caMCF had important chromosomal gains and losses and the earlier transformed cells trMCF showed small genomic changes (16) ; this could explain why ATRA was only effective as a re-differentiation agent in the early transformed breast epithelial cells. Different studies indicate that epigenetic modifications play important roles in RA transcriptional regulation (20) (21) (22) (23) (24) . Histones have a long N-terminal tail extending outside the nucleosome that is subject to acetylation, phosphorylation, and methylation (25) . In the absence of RA, co-repressive elements (SMRT, NCoR and SIN3A) inhibit transcription; the presence of RA releases co-repressors and histone deacetylases ALDH1A3↓, CCND1↓, TGFBR2↓, TGM2 ↓,  ALDH1A3↑, CCND1↑, TGFB2↑, TGM2↑,  receptor signaling  TFDP1↓, ALDH3A2↑, CYP1B1↑  TFDP1↑, ALDH3A2↓, CYP1B1↓  Other genes: CDKN1A↓, JUN↓ ALDH7A1↑,  Other genes: CCNE1↑, CCNE2↑, CDK6↑,  CSNK2A1↑, TGFB1↑, MAPK1↑, NFE2L2↑  DHFR↑, IL1B↑, IL6↑, NR2F1↑, NRIP1↑,  POLA1↑ ALDH3B2↓, ARNT↓, NCOA3↓,  HSPB2↓, ALDH6A1↓   RAR activation  ALDH1A3↓, DHRS9↓, NSD1↓, TGFB2↓,  ALDH1A3↑, DHRS9↑, NSD1↑, TGFB2↑,  CSNK2A2↑, PIK3CD↑, PRMT2↑, Molecular  TGFB2↓, TGFBR2↓, CCND1↓, FZD8↓,  TGFB2↑, TGFBR2↑, CCND1↑, FZD8↑,  mechanisms  PLCB4↓, RABIF↓, RHOF↓, GNA13↑,  PLCB4↑, RABIF↑, RHOF↑, GNA13↓,  of cancer  GNAI1↑, CD44↑  GNAI1↓, CD44↓  Other genes: CDKN1A↓, CTNNB1↓, FYN↓,  Other genes: APC↑, CCNE1↑, CCNE2↑,  IRS1↓, JUN↓, SMAD4↓, TCF4↓, XIAP↓,  CDC25A↑, CDK6↑, CYCS↑, E2F2↑,  PIK3CD↑, TCF3↑, TGFB1↑, GNAL↑,  MAP2K1↑, MAPK13↑, PRKAR2B↑,  MAPK1↑, MAPK14↑  RAPGEF3↑, RBL1↑, TFDP1↑, ARHGEF10↓,  FOXO1↓, HHAT↓, IRS1↓, NF1↓, PAK3↓,  PIK3CD↓, Recently, analysis of gene expression array datasets of different FDA approved drugs revealed that ATRA (tretinoin) is a drug that is negatively associated with cancer stem cell (CSC) enriched gene expression signature (26) . We found that ATRA treatment reduced the expression of the stem cell marker CD44 in early transformed cells. ATRA exerts effects on stem cell differentiation in part via the modulation of the epigenome. Numerous enzymes that alter the modifications on histones are involved in transcriptional activation of specific genes in stem cells, and many of these enzymes are modulated by RA treatment of stem cells (27) . The expression of several genes encoding enzymes involved in chromatin modifications such as MGEA5, ATF-2, KDM5B, PRMT2, PHF21A and NSD1 were dysregulated in trMCF clone 11, reaching normal levels after ATRA treatment. Others have shown that in breast cancer, retinoids are effective inhibitors of breast cancer cells at early stages of tumor progression, but their effectiveness diminishes as the tumors become more aggressive (28) . Our results support these findings.
Our results show that the RA concentration is important to induced re-differentiation of early transformed breast epithelial cells. The treatment of transformed cells with either 10 -7 or 10 -8 M ATRA did not induced any change in morphology although, cells were able to form tubules after treatment with 10 -5 and 10 -6 M ATRA, more tubules being developed after treatment with 10 -6 M (1 µM) ATRA. Little is known about the genomic targets and effects of the different isoforms of the RARs and mechanism or extent of crosstalk between RA signaling and other signaling pathways. It has been recently shown that RAR binding through the genome is highly coincident with estrogen receptor α binding, resulting in widespread crosstalk of RA and estrogen signaling to antagonistically regulate breastcancer associated genes (29) . Our gene expression studies determined 443 genes which defined a signature of ATRA re-programming effect in early transformed breast epithelial cells; these genes were dysregulated in the early transformed cells and they reached normal levels after the cells were treated with 10 -6 M ATRA. Genes from the aryl hydrocarbon receptor (AhR), retinoic acid receptor (RAR) and the xenobiotic pathways were dysregulated in the early transformed breast epithelial cells and their expression reached normal levels after ATRA treatment. It has been shown that there is an interaction between AhR and RAR activation and that AhR not only binds to polycyclic aromatic hydrocarbon family of environmental contaminants but also to some synthetic retinoids (30, 31) .
N-(4-hydoxyphenyl) retinamide (fenretinide or 4HPR) is a synthetic retinoid that is currently one of the most promising clinically tested retinoids. The modification of the carboxyl end of all-trans RA with N-4-hydroxyphenyl group resulted in increased efficacy as a chemoprevention agent as well as reduced toxicity when compared with other retinoids (32) . Animal models have demonstrated that treatment with fenretinide prevents chemically induced cancers of the breast, prostate, bladder and skin (33) (34) (35) (36) .
In conclusion, our results showed that 1 µM ATRA was able to re-differentiate transformed cells at early stages of the neoplastic process and antagonistically regulated breast cancer associated genes. Our results support previous findings that 1 µM ATRA could be used as a chemo-preventive agent to inhibit the progression of premalignant lesions of the breast.
